Periodic Reporting for period 1 - SYST-iMYC (Development of an effective and safe systemic Myc inhibitor for the treatment of multiple cancer types.)
Periodo di rendicontazione: 2018-07-01 al 2019-12-31
In the project Syst-iMYC, we proposed to develop an innovative approach to inhibit Myc, a non-redundant and “most-wanted” therapeutic target in human cancer. Thanks to the ERC-2013-CoG n° 617473, linked to this PoC, we previously proved that Omomyc, a Myc mutant designed by Dr. Soucek and known to be the best direct Myc inhibitor characterized to date, presented unexpected cell-penetrating properties when produced as a purified Omomyc polypeptide. Such a polypeptide displayed anti-tumorigenic effect upon local administration to mice bearing lung and brain tumors, and could therefore become a first clinically-viable direct Myc inhibitor. With this ERC PoC, we made a further step towards a more clinically viable product, developing a new drug based on an Omomyc variant that enables systemic treatment of several cancer types including lung, breast, lymphoma, and melanoma. The forecasted peak revenue for such first-in-class drug in these indications could reach 2.612 M€ annually.
We are happy to confirm that, at the end of this project, we have a product active in vitro and in vivo and ready to enter clinical trials Phase I/II in patients in January 2021, to then continue its commercialization. During the duration of this project, we achieved essential milestones for the development of this innovative therapeutic polypeptide: we established its activity in vitro and in vivo, we defined its toxicology profile in mice and prepared for regulatory non-clinical studies in two other animal species, put together a commercial package (including market potential, IPR portfolio and strategy, and feedback from VCs) and established the feasibility of its industrial production.
We are happy to confirm that, at the end of this project, we have a product active in vitro and in vivo and ready to enter clinical trials Phase I/II in patients in January 2021, to then continue its commercialization. During the duration of this project, we achieved essential milestones for the development of this innovative therapeutic polypeptide: we established its activity in vitro and in vivo, we defined its toxicology profile in mice and prepared for regulatory non-clinical studies in two other animal species, put together a commercial package (including market potential, IPR portfolio and strategy, and feedback from VCs) and established the feasibility of its industrial production.